The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study.
- Author:
Jung Kwon KIM
1
;
Jung Jun KIM
1
;
Taek Won GANG
2
;
Tae Kyun KWON
3
;
Hong Sup KIM
4
;
Seung Chul PARK
5
;
Jae-Shin PARK
6
;
Jong-Yeon PARK
7
;
Seok Joong YOON
8
;
Youn-Soo JEON
9
;
Jin Seon CHO
10
;
Kwan Joong JOO
11
;
Sung-Hoo HONG
12
;
Seok-Soo BYUN
1
Author Information
- Collective Name:Korean Urological Oncology Society
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords: Korean population; efficacy; hormonal treatment; prostate cancer; safety; trend
- MeSH: Aged; Androgen Antagonists/therapeutic use*; Antineoplastic Agents, Hormonal/therapeutic use*; Cholesterol/blood*; Drug Therapy, Combination; Humans; Leuprolide/therapeutic use*; Male; Middle Aged; Prostatic Neoplasms/pathology*; Quality of Life; Receptors, LHRH/agonists*; Republic of Korea; Testosterone/blood*; Treatment Outcome; Triglycerides/blood*
- From: Asian Journal of Andrology 2019;21(2):115-120
- CountryChina
- Language:English
- Abstract: We aimed to evaluate the current nationwide trend, efficacy, safety, and quality of life (QoL) profiles of hormone treatment in real-world practice settings for prostate cancer (PCa) patients in Korea. A total of 292 men with any biopsy-proven PCa (TanyNanyMany) from 12 institutions in Korea were included in this multi-institutional, observational study of prospectively collected data. All luteinizing hormone-releasing hormone (LHRH) agonists were allowed to be investigational drugs. Efficacy was defined as (1) the rate of castration (serum testosterone ≤50 ng dl-1) at 4-week visit and (2) breakthrough (serum testosterone >50 ng dl-1 after castration). Safety assessments included routine examinations for potential adverse events, laboratory tests, blood pressure, body weight, and bone mineral density (BMD, at baseline and at the last follow-up visit). QoL was assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26). The most common initial therapeutic regimen was LHRH agonist with anti-androgen (78.0%), and the most commonly used LHRH agonist for combination and monotherapy was leuprolide (64.0% for combination and 58.0% for monotherapy). The castration and breakthrough rates were 78.4% and 6.6%, respectively. The laboratory results related to dyslipidemia worsened after 4 weeks of hormone treatment. In addition, the mean BMD T-score was significantly lower at the last follow-up (mean: -1.950) compared to baseline (mean: -0.195). The mean total EPIC-26 score decreased from 84.8 (standard deviation [s.d.]: 12.2) to 78.3 (s.d.: 8.1), with significant deterioration only in the urinary domain (mean: 23.5 at baseline and 21.9 at the 4-week visit). These findings demonstrate the nationwide trend of current practice settings in hormone treatment for PCa in Korea.
